{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:49Z","timestamp":1761016969103},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T00:00:00Z","timestamp":1342569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00115-012-3598-2","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T11:25:57Z","timestamp":1343733957000},"page":"1292-1299","source":"Crossref","is-referenced-by-count":10,"title":["Retardiertes vs. schnell freisetzendes Oxcarbazepin bei therapierefrakt\u00e4rer fokaler Epilepsie"],"prefix":"10.1007","volume":"83","author":[{"given":"B.J.","family":"Steinhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schulze-Bonhage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wangemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Elger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,18]]},"reference":[{"key":"3598_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-199400910-00002","volume":"9","author":"Bareggi","year":"1994","unstructured":"Bareggi SR, Tata MR, Guizzaro A et al (1994) Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Int Clin Psychopharmacol 9:9\u201316","journal-title":"Int Clin Psychopharmacol"},{"key":"3598_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1528-1157.1994.tb05939.x","volume":"35","author":"Baruzzi","year":"1994","unstructured":"Baruzzi A, Albani F, Riva R (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35(Suppl 3):14\u201319","journal-title":"Epilepsia"},{"key":"3598_CR3","unstructured":"Bialer M (2002) Oxcarbazepine. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH (Hrsg) Antiepileptic drugs, 5.\u00a0Aufl. Lippincott, Williams & Wilkins, Philadelphia, S\u00a0459\u2013465"},{"key":"3598_CR4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00023210-200721090-00005","volume":"21","author":"Bialer","year":"2007","unstructured":"Bialer M (2007) Extended-release formulations for the treatment of epilepsy. CNS Drugs 21:765\u2013774","journal-title":"CNS Drugs"},{"key":"3598_CR5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1212\/01.wnl.0000172932.95985.51","volume":"65","author":"Ficker","year":"2005","unstructured":"Ficker DM, Privitera M, Krauss G et al (2005) Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 65:593\u2013595","journal-title":"Neurology"},{"key":"3598_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"Flesch","year":"2004","unstructured":"Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185\u2013203","journal-title":"Clin Drug Investig"},{"key":"3598_CR7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","volume":"43","author":"Grant","year":"1992","unstructured":"Grant SM, Faulds D (1992) Oxcarbazepine: a review of its pharmacological and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 43:873\u2013888","journal-title":"Drugs"},{"key":"3598_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1157.1994.tb05938.x","volume":"35","author":"Lloyd","year":"1994","unstructured":"Lloyd P, Flesch G, Dieterle W (1994) Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35(Suppl 3):10\u201313","journal-title":"Epilepsia"},{"key":"3598_CR9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yebeh.2010.04.022","volume":"18","author":"Milovan","year":"2010","unstructured":"Milovan D, Almeida L, Romach MK et al (2010) Effect of eslicarbazepine actetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav 18:366\u2013373","journal-title":"Epilepsy Behav"},{"key":"3598_CR10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.yebeh.2005.08.015","volume":"7","author":"Lutz","year":"2005","unstructured":"Lutz MT, Helmstaedter C (2005) EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav 7:708\u2013714","journal-title":"Epilepsy Behav"},{"key":"3598_CR11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0404.2004.00291.x","volume":"109","author":"Miller","year":"2004","unstructured":"Miller AD, Krauss GL, Hamzeh FM (2004) Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 109:374\u2013377","journal-title":"Acta Neurol Scand"},{"key":"3598_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.yebeh.2004.01.009","volume":"5","author":"Pellock","year":"2004","unstructured":"Pellock JM, Smith MC, Cloyd JC et al (2004) Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav 5:301\u2013307","journal-title":"Epilepsy Behav"},{"key":"3598_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s10309-007-0251-3","volume":"20","author":"Steinhoff","year":"2007","unstructured":"Steinhoff BJ (2007) Unterschiede in den biopharmazeutischen Eigenschaften von Oxcarbazepinpr\u00e4paraten k\u00f6nnen die Vertr\u00e4glichkeit insbesondere bei h\u00f6heren Tagesdosen relevant beeinflussen. Z Epileptol 20:76\u201380","journal-title":"Z Epileptol"},{"key":"3598_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10309-009-0017-1","volume":"22","author":"Steinhoff","year":"2009","unstructured":"Steinhoff BJ (2009) Verz\u00f6gert freigesetztes Oxcarbazepin \u2013 \u00dcberblick und klinische Erfahrungen. Z Epileptol 22:2\u20138","journal-title":"Z Epileptol"},{"key":"3598_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/17512433.2.2.155","volume":"2","author":"Steinhoff","year":"2009","unstructured":"Steinhoff BJ (2009) Oxcarbazepine extended-release formulation in epilepsy. Expert Rev Clin Pharmacol 2:155\u2013162","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3598_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.eplepsyres.2009.09.013","volume":"87","author":"Steinhoff","year":"2009","unstructured":"Steinhoff BJ, Wendling A-S (2009) Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages. Epilepsy Res 87:259\u2013259","journal-title":"Epilepsy Res"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-012-3598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-012-3598-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-012-3598-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:14:50Z","timestamp":1558588490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-012-3598-2"}},"subtitle":["Eine offene multizentrische, randomisierte kontrollierte Studie"],"short-title":[],"issued":{"date-parts":[[2012,7,18]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["3598"],"URL":"https:\/\/doi.org\/10.1007\/s00115-012-3598-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,18]]}}}